CG Oncology, Inc. Common stock (CGON) Financials
Key financial figures for CG Oncology, Inc. Common stock (Q3 2026).
CG Oncology reported a wider Q2 2026 net loss of $79.1 million as R&D and G&A spend rose, while cash and marketable securities held near $1.0 billion, which management says funds operations through 2029. Net loss was $79.1 million, or $(0.90) per share, versus a $41.4 million net loss, or $(0.54) per share, in the prior-year quarter. R&D expenses rose to $54.7 million from $31.3 million a year ago, driven by higher clinical trial costs (including CMC) and increased headcount. G&A expenses rose to $29.0 million from $17.4 million a year ago, primarily on higher personnel-related costs. Commercial, development, and collaboration revenue was $1.16 million in the quarter, versus none in the prior-year quarter. On the outlook: Company states existing cash, cash equivalents and marketable securities are expected to fund operations through 2029; anticipates PIVOT-006 Phase 3 topline data in the near-term and completion of the BLA submission for HR BCG-unresponsive NMIBC in Q4 2026. Figures are for Q2 2026, as CG Oncology reported them.
- Revenue
- $2M
- Net Income
- $0
- EPS
- $-0.64
- Total Assets
- $1.0B
- Operating Cash Flow
- -$48M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $2M | $0 | -$0.64 | -3943.2% | -$49M |
| Q2 FY2026 | $1M | -$79M | -$0.90 | -7467.68% | -$47M |
| Q1 FY2026 | $1M | -$60M | -$0.71 | -6130.1% | -$57M |
| Q4 FY2025 | $2M | -$41M | -$0.52 | -2097.33% | -$36M |
| Q3 FY2025 | $2M | -$44M | -$0.57 | -3068.97% | -$39M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $4M | -$161M | -$2.08 | -4722.13% | -$132M |
| FY2024 | $1M | -$88M | -$1.41 | -10067.25% | -$79M |
| FY2023 | $204K | -$49M | -$1.02 | -27180.88% | -$46M |
Frequently asked questions
What was CG Oncology's revenue last quarter?
CG Oncology reported revenue of $1.6 million for Q3 FY2026, down 3.7% from the same period a year earlier.
Is CG Oncology profitable?
Not in its most recent reported period. CG Oncology reported a net loss of $0.00 for Q3 FY2026, a net margin of 0% on revenue.
How has CG Oncology's margin trended?
Operating margin was -3943.2% in Q3 FY2026, compared with -3068.97% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
When does CG Oncology report next?
CG Oncology is scheduled to report Q3 2026 results on 2026-11-13. That date is an estimate and has not been confirmed by the company.
Full income statement, balance sheet and cash flow for CG Oncology, Inc. Common stock on SentiSense, with up to forty quarters and twenty fiscal years of history.